Experimental Neurosurgery
Experimental Neurosurgery, Department of Neurosurgery
Neuroscience Center
Frankfurt University Hospital
Heinrich-Hoffmann-Str. 7
D-60528 Frankfurt am Main
Tel ++49 69-6301-6923
Fax ++49 69- 6301-5575
Thomas.Broggini@unimedizin-ffm.de
Current Scientific Focus/ Research Interest
Our research mainly focuses on the molecular mechanisms of apoptosis, non-apoptotic cell death and autophagy. We are elucidating the molecular events leading to gliomagenesis, as well as apoptosis deficiency and therapy resistance of glioblastoma (GBM), the most malignant and deadly human primary brain tumor. Based on these investigations, we are trying to develop novel genetic insight-based therapeutic strategies for the treatment of gliomas in cell culture models and in transplantable syngeneic animal tumor models. One recent example is our finding that the natural anticancer drug AT-101 triggers an excessive, cell-lethal type of mitophagy - the selective removal of mitochondria via the autophagosomal/lysosomal pathway [https://pubmed.ncbi.nlm.nih.gov/29938581/ ].
Group members
Prof. Dr. rer. nat. Donat Kögel
Tel ++49 69-6301-6923
Prof. Dr. Donat Kögel studied Biology at the Ruprecht-Karls-University of Heidelberg. To obtain his diploma in 1991, he investigated the AZF region of the Y chromosome at the Dept. of Human Genetics under the supervision of Prof. F. Vogel. In 1995 he received his PhD title (Dr. rer. nat.) for his work on the human foamy virus at the German Cancer Research Center (DKFZ) under the supervision of Prof. Rolf Flügel. From 1995 to 1999 he worked as a PostDoc at the Institute of Genetics at the Friedrich-Wilhelms-University Bonn in the lab of Prof. Karl-Heinz Scheidtmann, focusing on novel members of the death-associated protein (DAP) kinase family and regulation of the tumor suppressor protein p53 by phosphorylation. From 2000 to 2002 he worked as a group leader at the Interdisciplinary Center for Clinical Research of the Westphalian Wilhelms-University Münster in the lab of Jochen Prehn working, inter alia, on the physiological and pathophysiological roles of the amyloid precursor protein (APP), pro-apoptotic BH3-only proteins and mitochondrial control of apoptosis and other types of regulated cell death. Hereafter he relocated to the Dept. of Neurosurgery in Frankfurt, continuing his studies on the pathophysiological stress stimuli and cell death signalling pathways implicated in apoptotic and non-apoptotic neuron death in stroke, Alzheimer´s disease and Parkinson´s disease while simultaneously establishing his focus on molecular cancer research/experimental neurooncology. After obtaining his habilitation in 2005 he assumed the position as head of the Experimental Neurosurgery at the Neuroscience Center. In 2012 he was promoted to assistant professor (Apl.-Prof.) and since 2018 he is an active faculty member of the German Consortium for Translational Cancer Research (DKTK) at the Frankfurt site. His current research projects aim at deciphering the relevance of organelle-specific types of autophagy for cancer cell death (as part of SFB1177, a collaborative research center on autophagy in Frankfurt and Mainz [http://www.sfb1177.de]), and at determining the molecular mechanisms of intrinsic and acquired therapy resistance in gliomas, but also in other very aggressive cancer entities such as triple-negative breast cancer (funded by the DFG) with a particular focus on pro-survival family members of the Bcl-2 family and the co-chaperone BAG3.
Dr. rer. nat. Benedikt Linder
Tel ++49 69-6301-6930
Dr. Benedikt Linder studied Biology at the Justus-Liebig-University of Giessen where he obtained his Masters degree in 2011. He completed his Master Thesis in the lab of Prof. Dr. Reinhard Dammann at the Institute of Genetics on his work about epigenetic regulation of ribosomal genes in cancer. Afterwards he located to Göttingen where did his PhD at the University Medical Center in the lab of Prof. Dr. Heidi Hahn at the Institute of Human Genetics within the Tumor Genetics group. He received his degree in 2015 on his work about the interaction of Hedgehog and Vitamin D receptor signalling pathways in Basal Cell Carcinoma. Since then he relocated to his current position where he initially worked on targeted therapies against glioblastoma using lipopolyplexed siRNAs in murine models. Additionally he initiated the work on glioblastoma stem-like cells in the lab, showing that the stem-like phenotype can be successfully inhibited using arsenic trioxide. Very recently, after obtaining start-up from GRADE [https://www.uni-frankfurt.de/51934152/Start], the graduate program of the Goethe University, he received DFG-funding for the continuation on his work on the targeting of this cell population and now heads a junior research group within the Experimental Neurosurgery.
Lisa Henkel
Tel ++49 69-6301-6940
Lisa Henkel studied Biological Sciences (B.Sc.) at the Goethe-University of Frankfurt and received her degree in 2016. During her Bachelor Thesis in the lab of Prof. Dr. Anna Starzinski-Powitz at the Institute of Cell Biology & Neurosciences, she analysed the novel transmembrane protein Shrew-1 and his interaction partners. Afterwards she studied Molecular Medicine (M. Sc.) also at the Goethe-University and received her Master’s degree in 2018. After joining the Experimental Neurosurgery, she completed her Master Thesis about the genetic and mitochondrial control of autophagy induction and autophagic cell death in glioblastoma cells. Since then she is working on the identification of the molecular determinants of autophagic and mitophagic cell death in glioblastoma as a doctoral student.
Caterina Klein
Tel ++49 69-6301-6940
Caterina Klein studied Biology at the Johannes Gutenberg University Mainz where she acquired her Bachelor’s degree in 2017. She passed her Bachelor thesis in the lab of Prof. Dr. Roland Strauss at the Institute of Developmental Biology and Neurobiology about depression in the model system Drosophila melanogaster by using genetic methods. Subsequently, she studied Molecular Medicine at the Goethe University Frankfurt am Main. She obtained her Master’s degree in 2019 and wrote her Master thesis in the lab of Prof. Dr. Dorothea Schulte at the Neurological Institute (Edinger Institute) about the contribution of calpains to the invasive phenotype of glial tumours. Currently, Caterina is a PhD student at the Experimental Neurosurgery. She is investigating the oncogenic and anti-apoptotic function of BAG3 and its client proteins, as well as their potential as pharmacological targets in the highly therapy-resistant cancers glioblastoma and triple negative breast cancer. Additionally, she is investigating novel BcL-xL and BAG3 inhibitors for their anticancer and pro-apoptotic effects in these cancer entities.
Johanna Ertl
Tel ++49 69-6301-6940
Johanna Ertl is a master student (Molecular Medicine) conducting her master thesis about genes responsible for radiation resistance in glioblastoma cells.
S0679259@stud.uni-frankfurt.de
Anna-Lena Possmeyer
Tel ++49 69-6301-6940
Anna-Lena Possmayer is a master student (Biowissenschaften) testing novel treatment options against glioblastoma stem-like cells and analyses factors causing differential responses.
Amaia Georgadi
Tel ++49 69-6301-84051
Amalia Georgadi is a master student (Molekulare Biowissenschaften) analysing potential drug candidates that induce autophagic cell death in glioblastoma cells.
Alicia Schiebler
Tel ++49 69-6301-6940
Alicia Schiebler is a master student (Molecular Medicine) deciphering migration and invasion mechanism of glioblastoma stem-like cells.
alicia.sh@web.de
Hildegard König
Tel ++49 69-6301-84051
Hildegard König joined the Experimental Neurosurgery as a medical technical assistant in 2003, providing exceptional assistance and management ever since.
News
Our new publication in the journal Autophagy: https://pubmed.ncbi.nlm.nih.gov/33461384/
Our new publication in the journal Matrix Biology: https://pubmed.ncbi.nlm.nih.gov/33290835/
Dr. Linder received funding from the DFG to study Glioma stem-like cells: https://aktuelles.uni-frankfurt.de/forschung/medizin-innovative-ansaetze-zur-erforschung-von-hirntumoren/
Prof. Kögel and Dr. Linder, together with Prof. Christel Herold-Mendes from the University of Heidelberg, are Guest-Editors for a Special Edition of the Journal Cancer: “Targeted Therapies for the Treatment of Glioblastoma” The deadline has been extended until the end of 2021 https://www.mdpi.com/journal/cancers/special_issues/Targeted_Therapies_Glioblastoma
A recent review from our lab was selected for the cover art of Biology, Volume 8, Issue 4: https://www.mdpi.com/2079-7737/8/4
Alumni
Dr. Janina Remy
Dr. Nina Meyer
Dr. Patrick Antonietti
Dr. Preeti Yadav
Dr. Arpita Kundu
Dr. Nelli Milosch
Dr. Noppasin Takerngdej
Katharina Arndt, B.S.
Julia Konovalova, B.S.
Selected publications
Linder, B., A. Wehle, S. Hehlgans, F. Bonn, I. Dikic, F. Rodel, V. Seifert and D. Kögel. 2019. Arsenic Trioxide and (-)-Gossypol Synergistically Target Glioma Stem-Like Cells via Inhibition of Hedgehog and Notch Signaling. Cancers (Basel) 11(3).
Meyer N, Zielke S, Michaelis JB, Linder B, Warnsmann V, Rakel S, Osiewacz HD, Fulda S, Mittelbronn M, Münch C, Behrends C & Kögel D. 2018. AT 101 induces early mitochondrial dysfunction and HMOX1 (heme oxygenase 1) to trigger mitophagic cell death in glioma cells. Autophagy, 14, 1693-1709.
Antonietti P, Linder B, Hehlgans S, Mildenberger IC, Burger MC, Fulda S, Steinbach JP, Gessler F, Rödel F, Mittelbronn M & Kögel D. 2017. Interference with the HSF1/HSP70/BAG3 pathway primes glioma cells to matrix detachment and BH3 mimetic-induced apoptosis. Mol Cancer Ther, 16, 156-168.
Milosch N, Tanriöver G, Kundu A, Rami A, François JC, Baumkötter F, Weyer SW, Samanta A, Jäschke A, Brod F, Buchholz CJ, Kins S, Behl C, Müller UC & Kögel D. 2014. Holo-APP and G-protein-mediated signaling are required for sAPPα-induced activation of the Akt survival pathway. Cell Death Dis, 5, e1391.
Weissenberger J, Priester M, Bernreuther C, Rakel S, Glatzel M, Seifert V & Kögel D. 2010. Dietary curcumin attenuates glioma growth in a syngeneic mouse model by inhibition of the JAK1,2/STAT3 signaling pathway. Clin Cancer Res, 16, 5781-95.
Voss V, Senft C, Lang V, Ronellenfitsch MW, Steinbach JP, Seifert V & Kögel D. 2010. The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res, 8, 1002-16.
Concannon CG, Koehler BF, Reimertz C, Murphy BM, Bonner C, Thurow N, Ward MW, Villunger A, Strasser A & Kögel D, Prehn JH. 2007. Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway. Oncogene, 26, 1681-92.
Kögel D, Schomburg R, Copanaki E & Prehn JH. 2005. Regulation of gene expression by the amyloid precursor protein: inhibition of the JNK/c-Jun pathway. Cell Death Differ, 12, 1-9.
Reimertz C, Kögel D, Rami A, Chittenden T & Prehn JH. 2003. Gene expression during ER stress-induced apoptosis in neurons: induction of the BH3-only protein Bbc3/PUMA and activation of the mitochondrial apoptosis pathway. J Cell Biol, 162, 587-97.
Poppe M, Reimertz C, Düssmann H, Krohn AJ, Luetjens CM, Böckelmann D, Nieminen AL, Kögel D & Prehn JH. 2001. Dissipation of potassium and proton gradients inhibits mitochondrial hyperpolarization and cytochrome c release during neural apoptosis. J Neurosci, 21, 4551-63.